AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 AUG 1 - (NewsRx.com & NewsRx.net) -- NexMed, Inc., (NEXM), a developer of innovative topical treatments based on its proprietary drug delivery technology, announced preliminary clinical results for its phase II at-home-use study for the Femprox topical cream treatment for female sexual arousal disorder (FSAD).
Femprox incorporates alprostadil, a vasodilator, with the NexACT platform drug delivery technology. The results were announced at the 97th annual meeting of the American Urological Association (AUA) in Orlando, Florida.
The multicenter phase II study was a randomized, double-blind, placebo-controlled trial, designed to investigate the efficacy and safety of Femprox cream in 98 premenopausal women diagnosed with FSAD.
Patients who qualified for the study were randomly assigned to 1 of 4 dose levels, which included placebo, and were required to use Femprox at home up to 10 times during the 4-week trial.
The trial results ...
Source: HighBeam Research, NexMed releases preliminary Femprox results from first take-home...